Presepsin
Appearance
Presepsin (soluble CD14 subtype, sCD14-ST) is a 13-kDa-cleavage product of CD14 receptor.[1]
Function
[edit]Presepsin is a soluble PRR. Presepsin in the circulation is an indicator of monocyte-macrophage activation in response to pathogens.[1]
Clinical relevance
[edit]Several clinical studies have demonstrated that presepsin is a specific and sensitive marker for the diagnosis, severity assessment and outcome prediction of sepsis.[2][3][4] In addition, presepsin can be used for diagnosing infections in patients with a chronic inflammatory condition, such as liver cirrhosis.[5]
References
[edit]- ^ a b Chenevier-Gobeaux C, Borderie D, Weiss N, Mallet-Coste T, Claessens YE (October 2015). "Presepsin (sCD14-ST), an innate immune response marker in sepsis". Clinica Chimica Acta; International Journal of Clinical Chemistry. 450: 97–103. doi:10.1016/j.cca.2015.06.026. PMID 26164388.
- ^ Dupuy AM, Philippart F, Péan Y, Lasocki S, Charles PE, Chalumeau M, et al. (July 2013). "Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections". Annals of Intensive Care. 3 (1): 22. doi:10.1186/2110-5820-3-22. PMC 3708786. PMID 23837559.
- ^ Tong X, Cao Y, Yu M, Han C (2015). "Presepsin as a diagnostic marker for sepsis: evidence from a bivariate meta-analysis". Therapeutics and Clinical Risk Management. 11: 1027–33. doi:10.2147/TCRM.S84811. PMC 4494627. PMID 26170681.
- ^ Wu J, Hu L, Zhang G, Wu F, He T (2015). "Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis". PLOS ONE. 10 (7): e0133057. Bibcode:2015PLoSO..1033057W. doi:10.1371/journal.pone.0133057. PMC 4507991. PMID 26192602.
- ^ Papp M, Tornai T, Vitalis Z, Tornai I, Tornai D, Dinya T, et al. (November 2016). "Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis". World Journal of Gastroenterology. 22 (41): 9172–9185. doi:10.3748/wjg.v22.i41.9172. PMC 5107598. PMID 27895404.